Literature DB >> 15972496

Multiple insertional events, restricted by the genetic background, have led to acquisition of pathogenicity island IIJ96-like domains among Escherichia coli strains of different clinical origins.

Philippe Bidet1, Stéphane Bonacorsi, Olivier Clermont, Caroline De Montille, Naima Brahimi, Edouard Bingen.   

Abstract

We investigated the dissemination of pathogenicity island (PAI) II(J96)-like elements (hra, hly, cnf1, and pap) among 455 Escherichia coli isolates from children and adults with urinary tract infection (UTI), neonates with meningitis or colonized healthy neonates, and 74 reference strains by means of PCR phylogenetic grouping, ribotyping, and PCR analysis of virulence genes. Colocalization of these genes was documented by pulsed-field gel electrophoresis followed by Southern hybridization and long-range PCR (LRPCR) between the hra and the papG alleles. Site-specific insertion of the PAI was determined by LRPCR between hra and tRNA flanking sequences. hra, hly, and cnf1 were found in 113 isolates and consistently colocalized, constituting the backbone of PAI II(J96)-like domains. The prevalence of PAI II(J96)-like domains was significantly higher among UTI isolates than among neonatal meningitis and commensal isolates. These domains were restricted to a few ribotypes of group B2. In contrast to the consistent colocalization of hra, hly, and cnf1, the pap operon was varied: 12% of strains exhibited an allelic exchange of the papG class III allele (papGIII) for the papG class II allele (papGII) (only UTI isolates), and the pap operon was deleted in 23% of strains. No strains harbored papGIII outside the PAI, which appears to be the only source of this allele. PAI II(J96)-like domains were inserted in the vicinities of three different tRNAs--pheU (54%), leuX (29%), and pheV (15%)--depending on the genetic backgrounds and origins of the isolates. Multiple insertional events restricted by the genetic background have thus led to PAI II(J96) acquisition. Specific genetic backgrounds and insertion sites may have played a role in additional recombination processes for E. coli adaptation to different ecological niches.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15972496      PMCID: PMC1168593          DOI: 10.1128/IAI.73.7.4081-4087.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

Review 1.  Ecological fitness, genomic islands and bacterial pathogenicity. A Darwinian view of the evolution of microbes.

Authors:  J Hacker; E Carniel
Journal:  EMBO Rep       Date:  2001-05       Impact factor: 8.807

2.  Expression of cnf1 by Escherichia coli J96 involves a large upstream DNA region including the hlyCABD operon, and is regulated by the RfaH protein.

Authors:  Luce Landraud; Maryse Gibert; Michel R Popoff; Patrice Boquet; Michel Gauthier
Journal:  Mol Microbiol       Date:  2003-03       Impact factor: 3.501

Review 3.  Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury.

Authors:  Kwang Sik Kim
Journal:  Nat Rev Neurosci       Date:  2003-05       Impact factor: 34.870

4.  Prokaryotic chromosomes and disease.

Authors:  Jörg Hacker; Ute Hentschel; Ulrich Dobrindt
Journal:  Science       Date:  2003-08-08       Impact factor: 47.728

5.  Molecular analysis and experimental virulence of French and North American Escherichia coli neonatal meningitis isolates: identification of a new virulent clone.

Authors:  Stéphane Bonacorsi; Olivier Clermont; Véronique Houdouin; Christophe Cordevant; Naima Brahimi; Armelle Marecat; Colin Tinsley; Xavier Nassif; Marc Lange; Edouard Bingen
Journal:  J Infect Dis       Date:  2003-05-29       Impact factor: 5.226

6.  afa-8 Gene cluster is carried by a pathogenicity island inserted into the tRNA(Phe) of human and bovine pathogenic Escherichia coli isolates.

Authors:  L Lalioui; C Le Bouguénec
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

7.  Epidemiological correlates of virulence genotype and phylogenetic background among Escherichia coli blood isolates from adults with diverse-source bacteremia.

Authors:  James R Johnson; Michael A Kuskowski; Timothy T O'Bryan; Joel N Maslow
Journal:  J Infect Dis       Date:  2002-04-17       Impact factor: 5.226

8.  Phylogenetic analysis and prevalence of urosepsis strains of Escherichia coli bearing pathogenicity island-like domains.

Authors:  Martine Bingen-Bidois; Olivier Clermont; Stéphane Bonacorsi; Mustapha Terki; Naïma Brahimi; Chawki Loukil; Dominique Barraud; Edouard Bingen
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

9.  A uropathogenicity island contributes to the pathogenicity of Escherichia coli strains that cause neonatal meningitis.

Authors:  Véronique Houdouin; Stéphane Bonacorsi; Naima Brahimi; Olivier Clermont; Xavier Nassif; Edouard Bingen
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

10.  Efficient expression of the alpha-haemolysin determinant in the uropathogenic Escherichia coli strain 536 requires the leuX-encoded tRNA(5)(Leu).

Authors:  U Dobrindt; L Emödy; I Gentschev; W Goebel; J Hacker
Journal:  Mol Genet Genomics       Date:  2002-04-26       Impact factor: 3.291

View more
  11 in total

1.  High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease.

Authors:  Roman Kotlowski; Charles N Bernstein; Shadi Sepehri; Denis O Krause
Journal:  Gut       Date:  2006-10-06       Impact factor: 23.059

2.  Acquisition of a pathogenicity island in an Escherichia coli clinical isolate causing febrile urinary tract infection.

Authors:  S M Soto; S Zúñiga; P Ulleryd; J Vila
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-18       Impact factor: 3.267

3.  LeuX tRNA-dependent and -independent mechanisms of Escherichia coli pathogenesis in acute cystitis.

Authors:  Thomas J Hannan; Indira U Mysorekar; Swaine L Chen; Jennifer N Walker; Jennifer M Jones; Jerome S Pinkner; Scott J Hultgren; Patrick C Seed
Journal:  Mol Microbiol       Date:  2007-11-25       Impact factor: 3.501

4.  Comprehensive mutagenesis of the fimS promoter regulatory switch reveals novel regulation of type 1 pili in uropathogenic Escherichia coli.

Authors:  Huibin Zhang; Teodorus T Susanto; Yue Wan; Swaine L Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-30       Impact factor: 11.205

5.  Pathogenicity island markers, virulence determinants malX and usp, and the capacity of Escherichia coli to persist in infants' commensal microbiotas.

Authors:  Anna Ostblom; Ingegerd Adlerberth; Agnes E Wold; Forough L Nowrouzian
Journal:  Appl Environ Microbiol       Date:  2011-02-11       Impact factor: 4.792

6.  Phylogenetic groups and pathogenicity island markers in fecal Escherichia coli isolates from asymptomatic humans in China.

Authors:  Bin Li; Jing-yong Sun; Li-zhong Han; Xin-hong Huang; Qiang Fu; Yu-xing Ni
Journal:  Appl Environ Microbiol       Date:  2010-08-13       Impact factor: 4.792

7.  The Escherichia coli argW-dsdCXA genetic island is highly variable, and E. coli K1 strains commonly possess two copies of dsdCXA.

Authors:  Rebecca L Moritz; Rodney A Welch
Journal:  J Clin Microbiol       Date:  2006-11       Impact factor: 5.948

8.  Virulence factors in urinary Escherichia coli strains: phylogenetic background and quinolone and fluoroquinolone resistance.

Authors:  Gabriella Piatti; Alessandro Mannini; Maria Balistreri; Anna Maria Schito
Journal:  J Clin Microbiol       Date:  2007-12-05       Impact factor: 5.948

9.  Urinary tract infection in women: new pathogenic considerations.

Authors:  Ann E Stapleton
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.663

10.  Use of optical mapping to sort uropathogenic Escherichia coli strains into distinct subgroups.

Authors:  William R Schwan; Adam Briska; Buffy Stahl; Trevor K Wagner; Emily Zentz; John Henkhaus; Steven D Lovrich; William A Agger; Steven M Callister; Brian DuChateau; Colin W Dykes
Journal:  Microbiology (Reading)       Date:  2010-04-08       Impact factor: 2.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.